[Application of CA125 elimination rate constant K score in prognostic forecast of patients undergoing interval debulking surgery for high grade serous ovarian cancer].
H D Liu, H L Wu, L L Ma, Y Cui, S W Wang, G H Shen
{"title":"[Application of CA<sub>125</sub> elimination rate constant K score in prognostic forecast of patients undergoing interval debulking surgery for high grade serous ovarian cancer].","authors":"H D Liu, H L Wu, L L Ma, Y Cui, S W Wang, G H Shen","doi":"10.3760/cma.j.cn112141-20250102-00001","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the predictive value of the cancer antigen 125 (CA<sub>125</sub>) elimination rate constant K (KELIM) score for no visible residual disease (R0) and prognosis in high-grade serous ovarian carcinoma (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT)+interval debulking surgery (IDS). <b>Methods:</b> A retrospective analysis was conducted on 78 HGSOC patients treated with NACT+IDS at Beijing Hospital, from June 2014 to June 2024. The KELIM score was calculated, and its predictive value for R0 resection, chemotherapy response score (CRS), platinum-free interval (PFI), progression-free survival (PFS) time, and overall survival (OS) time was analyzed. <b>Results:</b> (1) The mean age at diagnosis was (61.9±9.9) years. The mean KELIM score was 1.1±0.4, with 44 patients having KELIM score≥1 and 34 having KELIM score <1. (2) Patients with KELIM score ≥1 had significantly higher rates of R0 resection (84% vs 56%; <i>P</i>=0.006), CRS3 grading (41% vs 0; <i>P</i><0.001), and PFI ≥6 months (84% vs 53%; <i>P</i>=0.04) compared to those with KELIM score <1. Additionally, the median PFS time (18.7 vs 13.2 months; <i>P</i><0.001) and OS time (34.8 vs 29.9 months; <i>P</i>=0.007) were significantly longer in the KELIM score ≥1 group. Chemosensitivity: patients with PFI <6 months had a significantly lower median KELIM score than those with PFI ≥6 months (0.8 vs 1.2; <i>P</i>=0.005). Surgical outcome: patients achieving R0 resection had a significantly higher median KELIM score than those without R0 (1.2 vs 0.7; <i>P</i><0.001). (3) Univariate analysis identified non-R0 resection, CRS3 grading, lack of poly adenosine diphosphate ribose polymerase (PARP) inhibitor maintenance therapy, and KELIM score <1 as significant risk factors for OS time (all <i>P</i><0.05). Multivariate analysis confirmed non-R0 resection (<i>HR</i>=3.78,95%<i>CI</i>: 1.13-12.66; <i>P</i>=0.031), no PARP inhibitor maintenance (<i>HR</i>=7.41,95%<i>CI</i>:1.82-30.15; <i>P</i>=0.005), and KELIM score <1 (<i>HR</i>=5.14,95%<i>CI</i>:1.41-18.72; <i>P</i>=0.013) as independent risk factors for OS time. <b>Conclusions:</b> The KELIM score may serve as a predictive marker for chemosensitivity, R0 resection, PFS time, and OS time in HGSOC patients undergoing NACT+IDS. KELIM score<1 is an independent risk factor for OS.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"461-468"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华妇产科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112141-20250102-00001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the predictive value of the cancer antigen 125 (CA125) elimination rate constant K (KELIM) score for no visible residual disease (R0) and prognosis in high-grade serous ovarian carcinoma (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT)+interval debulking surgery (IDS). Methods: A retrospective analysis was conducted on 78 HGSOC patients treated with NACT+IDS at Beijing Hospital, from June 2014 to June 2024. The KELIM score was calculated, and its predictive value for R0 resection, chemotherapy response score (CRS), platinum-free interval (PFI), progression-free survival (PFS) time, and overall survival (OS) time was analyzed. Results: (1) The mean age at diagnosis was (61.9±9.9) years. The mean KELIM score was 1.1±0.4, with 44 patients having KELIM score≥1 and 34 having KELIM score <1. (2) Patients with KELIM score ≥1 had significantly higher rates of R0 resection (84% vs 56%; P=0.006), CRS3 grading (41% vs 0; P<0.001), and PFI ≥6 months (84% vs 53%; P=0.04) compared to those with KELIM score <1. Additionally, the median PFS time (18.7 vs 13.2 months; P<0.001) and OS time (34.8 vs 29.9 months; P=0.007) were significantly longer in the KELIM score ≥1 group. Chemosensitivity: patients with PFI <6 months had a significantly lower median KELIM score than those with PFI ≥6 months (0.8 vs 1.2; P=0.005). Surgical outcome: patients achieving R0 resection had a significantly higher median KELIM score than those without R0 (1.2 vs 0.7; P<0.001). (3) Univariate analysis identified non-R0 resection, CRS3 grading, lack of poly adenosine diphosphate ribose polymerase (PARP) inhibitor maintenance therapy, and KELIM score <1 as significant risk factors for OS time (all P<0.05). Multivariate analysis confirmed non-R0 resection (HR=3.78,95%CI: 1.13-12.66; P=0.031), no PARP inhibitor maintenance (HR=7.41,95%CI:1.82-30.15; P=0.005), and KELIM score <1 (HR=5.14,95%CI:1.41-18.72; P=0.013) as independent risk factors for OS time. Conclusions: The KELIM score may serve as a predictive marker for chemosensitivity, R0 resection, PFS time, and OS time in HGSOC patients undergoing NACT+IDS. KELIM score<1 is an independent risk factor for OS.